Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

BL-1020

Small molecule · developed by BioLineRx

Phase 2 Most advanced trial (none active)
BLRX Developer
4 Registered trials

What is BL-1020?

BL-1020 is an investigational small-molecule drug studied in Healthy, Schizophrenia, Schizoaffective Disorder.

At a glance

Drug type
Small molecule
Therapy area
Psychiatry
Developer
BioLineRx, Ltd. (BLRX)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2
UNII
K1WO7H97QZ

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT00567710 Phase 2 Schizophrenia Completed BLRX
NCT00722176 Phase 2 Schizophrenia Completed BLRX
NCT00480571 Phase 2 Schizophrenia Completed BLRX
NCT00480246 Phase 1 Healthy Completed BLRX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

HealthySchizoaffective DisorderSchizophrenia

More from BioLineRx

BL-1021 Phase 1 BL-7010 Phase 1/2 BL-7040 Phase 2 CYP-1020 Phase 2/3

Follow BLRX, the company behind BL-1020

See BLRX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

BLRX catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.